Pharmacol. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. doi: 10.1016/j.ygyno.2006.04.002, Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. PH IV/PH FDC SC is standard of care for HER2-positive BC and usually given with chemotherapy, all of which can trigger anaphylaxis/hypersensitivity. The .gov means its official. -, A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. doi: 10.1093/annonc/mdy158. Epub 2017 Feb 24. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations Front Immunol. 2008;14(27):2892-901. doi: 10.2174/138161208786369803. In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. However, severe carboplatin-related hypersensitivity symptoms can be fatal, as in one of our cases. Unauthorized use of these marks is strictly prohibited. The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with >8 cycles or dose >3,500 mg. Cancer 109, 10721078. 44, 837840. This was the largest series of gynecological malignancies investigated for carboplatin-related hypersensitivity reactions.
Risk Factors of Hypersensitivity to Carboplatin in Patients with Clin Rev Allergy Immunol. In conclusion, in our present population of women with gynecological malignancies treated with platinum-based chemotherapy, 1 in 10 developed carboplatin-related hypersensitivity reactions.
Carboplatin-related hypersensitivity reactions sometimes result in premature discontinuation of treatment (Schwartz et al., 2007). MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Nitipir C, Parosanu A, Popa AM, Cotan H, Olaru M, Iaciu C, Orlov Slavu C. Cureus. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). The most commonly exhibited symptom/sign was hypotension (10.7%), followed by anaphylaxis (8.0%) and desaturation (6.7%). 15, 780784. Access all the congress resources: webcasts, news, press, posters, videos and much more. Copyright 2017 Tai, Tai, Hsu, Lee, Chen, Chiang, Chen, Chen and Cheng. doi: 10.1007/s10147-014-0731-1. The imaging findings follow the American Thoracic Society and European Respiratory Society classification of interstitial pneumonia. For salvage chemotherapy in the case of recurrent disease, we administered chemotherapeutic regimens including carboplatin with paclitaxel, gemcitabine, or liposomal doxorubicin. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. This review provides insight into the current knowledge of drug allergy and anaphylaxis to cancer and chronic inflammatory diseases drugs, the mechanisms of drug desensitization and its applications to personalized medicine. (2009). Table 5. Most events occurred during chemotherapy. Table 5 reports the incidences of carboplatin hypersensitivity and patient characteristics reported in various investigations, including the present study. We also recorded the procedures applied to treat the hypersensitivity reactions and efforts to manage the side effects of carboplatin administration. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines (2017) 8 Pager Instructions Coverage Begins March 1, 2019 Coverage Ends: TBD 1. . Univariate analysis for potential risk factors of carboplatin-related hypersensitivity reactions were assessed by the chi-square or Kruskal-Wallis test for categorical variables. Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. Abe, A., Ikawa, H., and Ikawa, S. (2010).
ESMO Virtual Congress 2020 | OncologyPRO Oncol. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. These new ESMO Clinical Practice Guidelines provide tools to evaluate the risk of infusion reactions, to recognise the early signs and symptoms and include recommendations on how to document and manage them. . For more detailed information on the cookies we use, please check our Privacy Policy. A sincere thanks to the almost 24,000 participants who attended this year's annual congress! In the majority of ovarian cancer cases, primary management entails surgical staging or cytoreduction, followed by systemic chemotherapy (Ledermann et al., 2013). PMC The median patient age was 56 years (range 1694 years). Front Oncol. Wang, H. B., Shen, K., Yang, J. X., Huang, H. F., Li, Y., Wu, M., et al. doi: 10.3802/jgo.2013.24.4.342, Confino-Cohen, R., Fishman, A., Altaras, M., and Goldberg, A. J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 2017;40(3):120-127. doi: 10.1159/000458443. Int. The left side, Putative mechanism of protection against, Putative mechanism of protection against anaphylaxis during human desensitizations. ESMO Clinical Practice Guidelines Provide your patients with the best care options Supporting your clinical decisions with ESMO's regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. The symptoms and signs of the 75 women with carboplatin-related hypersensitivity reactions are given in Table 4. The MASCC/ESMO guidelines recommend that patients receiving HEC are given a dose of 20 mg dexamethasone on Day 1 to prevent acute emesis; however, if the NK 1 RAs aprepitant or netupitant are also used, a reduced dose of 12 mg dexamethasone is recommended. Necessary cookies enable core functionality. The independent sample t-test was used to evaluate how carboplatin cycle and dose correlated with the incidence of hypersensitivity and severe hypersensitivity reactions. government site. Bookshelf
Bayer to Highlight New Research at ESMO 2017 Congress Shah et al. (2015). 57, 163167. 17 This dose reduction is due to the ability of both aprepitant and netupitant to inhibit the metabolism of dexamethasone leading to higher . The incidence of carboplatin-related hypersensitivity correlated with cycle number and dose, with the first episode occurring at a median of 12 cycles and 6,816 mg. The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.ESMO-MCBS scores are included in ESMO Clinical Practice Guidelines to help further guide treatment decisions. Successful carboplatin desensitization in patients with proven carboplatin allergy. The ESMO guideline recommends patients receive surveillance by colonoscopy every 3 years beginning at age 25 for MLH1 and MSH2 mutation carriers and age 35 for MSH6 and PMS2 mutation carriers, or . Ann Oncol. and transmitted securely. Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Read guidelines by topic Latest Guidelines News Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Our findings also suggest that a history of drug or food allergies is a predictive factor for carboplatin-related hypersensitivity. Interactive/Pocket Guideline Interactive/Pocket Guideline Constipation in Advanced Cancer 1 2 3 (2005). Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. J. Gynecol. We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. 144, 7782. Before ESMO is a Swiss-registered not-for-profit organisation. Supportive. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014).
Management of toxicities from immunotherapy: ESMO Clinical Practice J. Gynecol. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). FOIA Women are more affected by drug allergy and up to 27% of women with ovarian and breast cancer develop carboplatin allergy after multiple cycles of treatment. Please enable it to take advantage of the complete set of features! A cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) across all pivotal trials cited in the current EMA P IV/PH FDC SC SmPCs. 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. NCT00567190, NCT02402712, NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854, NCT03674112. Death from anaphylaxis to cisplatin: a case report. (2016). Carriers of BRCA genes develop drug allergy after fewer exposures and can present with severe reactions, including anaphylaxis. A spotlight on alkaloid nanoformulations for the treatment of lung cancer. (2016). http://downloads.hindawi.com/journals/mbd/2010/207084.pdf, Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. Among 735 eligible women, 75 (10.2%) experienced a total of 215 carboplatin-related hypersensitivity reaction events. Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin. A total of 59 women experienced mild signs and symptoms (grades 1 and 2), including skin rash (69.3%), skin itching (64.0%), facial flushing (56.0%), dyspnea (41.3%), chest pain (25.3%), tachycardia (18.7%), paresthesias (16.0%), abdominal cramping (13.3%), and diaphoresis (12.0%). Oncol. Monitor. The ESMO Congress is the most influential annual meeting for oncology professionals in Europe. One patient who experienced a carboplatin-related hypersensitivity reaction progressed to respiratory arrest and died. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals, Provide your patients with the best care options, ESMO Guidelines: Real World Cases - Webinar Series. Request PDF | On Jul 13, 2017, Susana Rosell Kernen published Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines | Find, read and cite all the . These patients were provided with intravenous fluid infusion and medications, including corticosteroids, antihistamines, and oxygen application. Lacouture, V. Sibaud, P.A. 1; Mandac Smoljanovi, Inga 2. PMC (2013). ESMO is a Swiss-registered not-for-profit organisation. Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge.